Tracers / [18F]AlF-NOTA-iPD-L1
[18F]AlF-NOTA-iPD-L1
Also written as [F-18]AlF-NOTA-iPD-L1; [F-18]AlF-NOTA-iPD-L1/
- Radionuclide
- F-18 t½ 109.77 min
- Modality
- Therapy
- Production route
- —
- Stage
- Reported once
- Syntheses indexed
- 1
What it is
- Compound class
- NOTA-conjugated PD-L1-targeting cyclic peptide
- Target / mechanism
- PD-L1 (programmed cell death ligand-1) PMID 40733128
- Clinical application
- —
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | SPE | 29 ± 3% | 98.7 ± 1.2% | NOTA-iPD-L1 | 40733128 2025 Pharmaceutics 250 µL of the peptide solution (250 µg of peptide) was mixed with 555 MBq (150 µL) of [18F]AlF and incubated at 100 °C for 15 min — overall radiochemical labeling yield of 29 ± 3% (n = 3) |
Need this precursor?We can point you to suppliers for [18F]AlF-NOTA-iPD-L1, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 40733128. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 40733128: 'NOTA-iPD-L1'.